Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Mark L Levitt"'
Autor:
Faizal Z. Asumda, Nellie A. Campbell, Mohamed A. Hassan, Reza Fathi, Daniella F. Vasquez Rico, Melanie Kiem, Ethan V. Vang, Yo Han Kim, Xin Luo, Daniel R. O’Brien, Sarah A. Buhrow, Joel M. Reid, Michael J. Moore, Vered Katz Ben-Yair, Mark L. Levitt, Jennifer L. Leiting, Amro M. Abdelrahman, Xinli Zhu, Fabrice Lucien, Mark J. Truty, Lewis R. Roberts
Publikováno v:
Cancers, Vol 16, Iss 5, p 1050 (2024)
Upamostat is an orally available small-molecule serine protease inhibitor that is a highly potent inhibitor of trypsin 1, trypsin 2, trypsin 3 (PRSS1/2/3), and the urokinase-type plasminogen activator (uPA). These enzymes are expressed in many cancer
Externí odkaz:
https://doaj.org/article/b28f6e53a90c47cf8ff9a1d3118f22b6
Effect of Opaganib on Supplemental Oxygen and Mortality in Patients with Severe SARS-CoV-2 Pneumonia
Autor:
Fernando Carvalho Neuenschwander, Ofra Barnett-Griness, Stefania Piconi, Yasmin Maor, Eduardo Sprinz, Nimer Assy, Oleg Khmelnitskiy, Nikita Lomakin, Boris Mikhailovich Goloshchekin, Ewelina Nahorecka, Adilson Joaquim Westheimer Calvacante, Anastasia Ivanova, Sergey Vladimirovich Zhuravel, Galina Yurevna Trufanova, Stefano Bonora, Amer Saffoury, Ami Mayo, Yury Shvarts, Giuliano Rizzardini, Rogerio Sobroza de Mello, Janaina Pilau, Alexey Klinov, Benjamin Valente-Acosta, Oleg Olegovich Burlaka, Natalia Bakhtina, Maskit Bar-Meir, Ivan Nikolaevich Shishimorov, Jose Oñate-Gutierrez, Cristian Ivan Garcia Rincon, Tatiana Ivanovna Martynenko, Ludhmila Abrahão Hajjar, Ana Carolina Nazare de Mendonca Procopio, Krzystof Simon, Walter Gabriel Chaves Santiago, Adam Fronczak, Conrado Roberto Hoffmann Filho, Osama Hussein, Vladimir Aleksandrovich Martynov, Guido Chichino, Piotr Blewaska, Jacek Wroblewski, Sergio Saul Irizar Santana, Andres Felipe Ocampo Agudelo, Adam Barczyk, Rachael L. Gerlach, Eppie Campbell, Aida Bibliowicz, Reza Fathi, Patricia Anderson, Gilead Raday, Michal Klein, Clara Fehrmann, Gina Eagle, Vered Katz Ben-Yair, Mark L. Levitt
RationaleThere are few treatment options for severe COVID-19 pneumonia. Opaganib is an oral treatment under investigation.ObjectiveEvaluate opaganib treatment in hospitalized patients with severe COVID-19 pneumonia.MethodsA randomized, placebo-contro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac5a8655eb260c38557cc88d09eaf63c
https://doi.org/10.1101/2022.06.12.22276088
https://doi.org/10.1101/2022.06.12.22276088
Autor:
Kevin L, Winthrop, Alan W, Skolnick, Adnan M, Rafiq, Scott H, Beegle, Julian, Suszanski, Guenther, Koehne, Ofra, Barnett-Griness, Aida, Bibliowicz, Reza, Fathi, Patricia, Anderson, Gilead, Raday, Gina, Eagle, Vered Katz, Ben-Yair, Harold S, Minkowitz, Mark L, Levitt, Michael S, Gordon
Publikováno v:
Open Forum Infectious Diseases. 9
Background Opaganib, an oral sphingosine kinase-2 inhibitor with antiviral and anti-inflammatory properties, was shown to inhibit severe acute respiratory syndrome coronavirus 2 replication in vitro. We thus considered that opaganib could be benefici
Autor:
Charles D Smith, Lynn W Maines, Staci N Keller, Vered Katz Ben-Yair, Reza Fathi, Terry F Plasse, Mark L Levitt
Publikováno v:
Drug design, development and therapy. 16
The Covid-19 pandemic driven by the SARS-CoV-2 virus continues to exert extensive humanitarian and economic stress across the world. Although antivirals active against mild disease have been identified recently, new drugs to treat moderate and severe
Autor:
Scott Beegle, Alan W Skolnick, Mark L. Levitt, Michael S Gordon, Patricia Anderson, Harold S Minkowitz, Gina Eagle, Guenther Koehne, Gilead Raday, Kevin L. Winthrop, Adnan Rafiq, Reza Fathi, Aida Bibliowicz, Ofra Barnett-Griness, Vered Katz Ben-Yair, Julian Suszanski
BackgroundOpaganib, an oral sphingosine kinase-2 inhibitor with antiviral and anti-inflammatory properties, was shown to inhibit SARS-CoV-2 replication in vitro. We thus considered that opaganib could be beneficial for moderate to severe COVID-19 pne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11367e9baa18250ae680554587c233e6
https://doi.org/10.1101/2021.08.23.21262464
https://doi.org/10.1101/2021.08.23.21262464
Autor:
Yo Han Kim, Lewis R. Roberts, Jennifer L. Leiting, Nellie A. Campbell, Sarah A. Buhrow, Daniel R. O'Brien, Faizal Z. Asumda, Joel M. Reid, Mark L. Levitt, Mohamed A. Hassan, Michael J. Moore, Reza Fathi, Mark J. Truty, Vered Katz Ben-Yair, Xin Luo, Fabrice Lucien-Matteoni
Publikováno v:
Cancer Research. 80:3078-3078
Background: Upamostat is an orally available small molecule serine protease inhibitor that is a highly potent inhibitor of trypsin 1, trypsin 2 and trypsin 3 (PRSS1/2/3) as well as urokinase-type plasminogen activator (uPA) which are expressed in man
Autor:
Eva Louise Lange, Reza Fathi, Danielle T. Abramson, Mark L. Levitt, Jan K. Jensen, Terry F. Plasse, Christine R. Schar, Emil Oldenberg
Publikováno v:
Molecular Cancer Therapeutics. 17:B055-B055
WX-UK1, a multi-serine protease inhibitor, was believed to function primarily as a synthetic small-molecule inhibitor of urokinase (uPA). We now reveal that WX-UK1 is a potent and rather specific inhibitor of human trypsin-2 and human trypsin-3, and
Autor:
Terry F. Plasse, Christine R. Schar, Jan K. Jensen, Emil Oldenburg, Mark L. Levitt, Eric M. Towler, Eva Louise Lange, Reza Fathi, Danielle T. Abramson
Publikováno v:
Cancer Research. 78:4200-4200
WX-UK1 (the active metabolite of upamostat) was originally developed as an inhibitor of the serine protease urokinase (uPA) with a Ki ~1 uM. To identify more sensitive targets, we performed a bioinformatic analysis of the ~200 human trypsin-like seri
Autor:
Raphael Pfeffer, Zvi Symon, Bernice Oberman, Baruch Brenner, Mark L. Levitt, Yulia Kundel, Thomas Tichler, Raphael Catane, Siegal Sadezki
Publikováno v:
Tumori Journal. 94:469-473
Aims and Background To analyze the efficacy and toxicity of adjuvant chemotherapy followed by whole abdominal irradiation in the treatment of resectable gastric cancer with positive lymph nodes. Methods and Study Design Between 1996 and 1999, 10 pati
Autor:
Michal Shahar, Talia Golan, Uri Yogev, Aliza Ackerstein, Steve Raskin, Raanan Berger, Alexander M. Lesokhin, David Sidransky, Hana Gadassi, Mark L. Levitt
Publikováno v:
Molecular Cancer Therapeutics. 14:B30-B30
Scientific background: Activated macrophages, present in excess during natural inflammatory responses, bear the potential to kill and eradicate cancer cells. Efranat has developed cancer immunotherapy based on macrophage activation using a plasma pro